/ Portfolio /

PUSHING HEALTHCARE FORWARD

With an added value that extends far beyond capital, our portfolio companies enjoy an unprecedented access to a dedicated research and evaluation team boasting deep scientific and commercial backgrounds, as well as to the Medison’s clinical, commercial and regulatory knowledge, and to a wide network of global pharma partners. This comprehensive support helps our portfolio companies streamline development of breakthrough technologies that will ultimately bring better care to patients.

 
Medison I/<br />Equity Investments

Medison I/
Equity Investments

Direct investments in biotech companies across development stages.

PONTIFAX-MEDISON /<br />VENTURE DEBT FUND

PONTIFAX-MEDISON /
VENTURE DEBT FUND

PONTIFAX-MEDISON /<br />VENTURE DEBT FUND

In 2019 Pontifax and Medison launched a $150M venture lending fund. The fund provides non-dilutive funding to innovative clinical-stage life science companies.

Pontifax is a venture capital firm investing in ground-breaking innovation in the life sciences space with $625M capital managed across 5 funds. Since 2004, Pontifax have invested in 80 private and public companies across a range of therapeutic areas and development stages.

To learn more about the partner Pontifax:
www.pontifax.com/

PONTIFAX-MEDISON /<br />VENTURE DEBT FUND
Platforms

Platforms

Digital health incubator in cooperation with Amgen, Cleveland Clinic, Macabbi Healthcare Services and Shanghai Creation Investment Fund.

www.ehealthventures.com

LinkEdge is investment vehicle, supporting innovative projects from top academic institutions and medical centers.

www.linkedgeventures.com

ARROW

In-house hedge fund, focused on the global healthcare sector, with an emphasis on the biotech sector.